Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Venture Financing 15
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Private Equity 19
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Partnerships 20
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
Licensing Agreements 22
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Equity Offering 23
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Debt Offering 29
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Asset Transactions 33
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Acquisition 34
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc – Key Competitors 40
Acorda Therapeutics Inc – Key Employees 41
Acorda Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 44
Strategy And Business Planning 44
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 44
Financial Announcements 45
Oct 31, 2018: Acorda provides financial and pipeline update for third quarter 2018 45
Aug 02, 2018: Acorda provides financial and pipeline update for second quarter 2018 47
May 02, 2018: Acorda Provides Financial and Pipeline Update for First Quarter 2018 48
Feb 15, 2018: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017 50
Jan 08, 2018: Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference 52
Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 54
Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 56
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 58
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 60
Corporate Communications 62
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 62
Product News 63
04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 63
Clinical Trials 64
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 64
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 65
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 67
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc, Key Competitors 40
Acorda Therapeutics Inc, Key Employees 41
Acorda Therapeutics Inc, Subsidiaries 42
List of Figures
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10